Palatin Technologies Incorporated

Longevica Pharmaceuticals, Inc.

John H Dodd

Yi-Qun Shi

Shubh D Sharma

Wei Yang

Axel Metzger

Xin Chen

Gary Olson

Carl Spana

Elizabeth G Rowley

Marie Makhlina

James Bullington

A compound of the formula where R, R, R, R, R, R, and Rare as defined in the specification and claims, or an enantiomer, stereoisomer or diastereoisomer thereof, or a pharmaceutically acceptable salt thereof, and the use thereof in the treatment of diseases, disorders, syndromes and conditions responsive to modulation of a melanocortin receptor.

Orally active melanocortin receptor-4 compounds

The invention relates to methods, uses, compositions and formulations including a melanocortin receptor-4 agonist and a glucagon-like peptide-1 receptor agonist for treatment of obesity, diabetes, metabolic syndrome and related indications, diseases or disorders.

Therapies for obesity, diabetes and related indications

Melanocortin receptor-specific cyclic peptides of the formula where R, R, R, Rand Rare as defined in the specification, compositions and formulations including the peptides of the foregoing formula, and methods of preventing, ameliorating or treating melanocortin receptor-mediated diseases, indications, conditions and syndromes.

Melanocortin receptor-specific peptides

Melanocortin receptor-specific cyclic peptides of the formula where R, R, R, R, R, R, R, R, R, Rand z are as defined in the specification, compositions and formulations including the peptides of the foregoing formula, and methods of preventing, ameliorating or treating melanocortin receptor-mediated diseases, indications, conditions and syndromes.

Eukaryotic elongation factor 2 kinase inhibitors of the formula where R, R, R, R, R, R, R, R, R, R, Rand x are as defined in the specification, pharmaceutical compositions and formulations including compounds of the foregoing formula, and methods of preventing, ameliorating or treating indications, conditions, disorders or syndromes associated with elongation factor 2 phosphorylation.

Compounds inhibiting eukaryotic elongation factor 2 kinase activity

Melanocortin receptor-specific cyclic heptapeptides of the formulaZ-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Y&#x2003;&#x2003;(II)or a pharmaceutically acceptable salt thereof, where Z, Xaa, Xaa, Xaa, Xaa, Xaa, Xaa, Xaaand Y are as defined in the specification, compositions and formulations including the peptides of the foregoing formula, and methods of preventing, ameliorating or treating melanocortin receptor-mediated diseases, indications, conditions and syndromes.

Melanocortin receptor-specific heptapeptides

Melanocortin receptor-specific compounds of formula I below: wherein the variables are as defined in the specification, and enantiomers, diastereomers and pharmaceutically acceptable salts thereof. Compounds disclosed herein bind to one or more melanocortin receptors and may be an agonist, a partial agonist, an antagonist, an inverse agonist or an antagonist of an inverse agonist as to one or more melanocortin receptors, and may be employed for treatment of one or more melanocortin receptor-associated conditions or disorders.

Growing community of inventors

Spring Mills, PA, United States of America

John H Dodd